VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 48 of Oncotarget features Table 3, "Clinical responses per RECIST and clinical benefit rate based on age," by Subbiah, et al.
Table of Contents
Research Papers: Immunology
|
| Rituximab as a frontline therapy for adultonset minimal change disease with nephrotic syndrome |
|
https://doi.org/10.18632/oncotarget.25612
|
| 28799-28804 |
Research Papers
|
| Exhaled breath analysis for gastric cancer diagnosis in Colombian patients |
|
https://doi.org/10.18632/oncotarget.25331
|
| 28805-28817 |
|
| Comparison of plateletalbuminbilirubin PALBI albuminbilirubin ALBI and childpugh CP score for predicting of survival in advanced hcc patients receiving radiotherapy RT |
|
https://doi.org/10.18632/oncotarget.25522
|
| 28818-28829 |
|
| A single amino acid substitution in CXCL12 confers functional selectivity at the betaarrestin level |
|
https://doi.org/10.18632/oncotarget.25533
|
| 28830-28841 |
|
| Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors |
|
https://doi.org/10.18632/oncotarget.25571
|
| 28842-28848 |
|
| Involvement of antitumor <i>miR1243p</i> and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of <i>ITGA3</i> and <i>ITGB1</i> by <i>miR1243p</i> |
|
https://doi.org/10.18632/oncotarget.25599
|
| 28849-28865 |
|
| New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes |
|
https://doi.org/10.18632/oncotarget.25601
|
| 28866-28876 |
|
| Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma |
|
https://doi.org/10.18632/oncotarget.25608
|
| 28877-28896 |
|
| Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis |
|
https://doi.org/10.18632/oncotarget.25622
|
| 28897-28902 |
|
| Real world experience in lowdose ipilimumab in combination with PD1 blockade in advanced melanoma patients |
|
https://doi.org/10.18632/oncotarget.25627
|
| 28903-28909 |
|
| Marek’s disease virus oncoprotein Meq physically interacts with the chicken infectious anemia virusencoded apoptotic protein apoptin |
|
https://doi.org/10.18632/oncotarget.25628
|
| 28910-28920 |
|
| VATPasedependent repression of androgen receptor in prostate cancer cells |
|
https://doi.org/10.18632/oncotarget.25641
|
| 28921-28934 |
|
| Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomographyguided surgery with <sup>64</sup>Culabeled cetuximab to treat early and latephase peritoneal dissemination in human gastrointestinal cancer xenografts |
|
https://doi.org/10.18632/oncotarget.25649
|
| 28935-28950 |
|
| MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locallyadvanced rectal adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.25652
|
| 28951-28964 |
|
| EGFR overexpression is not common in patients with head and neck cancer Cell lines are not representative for the clinical situation in this indication |
|
https://doi.org/10.18632/oncotarget.25656
|
| 28965-28975 |
|
| Targeting CREBbinding protein overrides LPS induced radioresistance in nonsmall cell lung cancer cell lines |
|
https://doi.org/10.18632/oncotarget.25665
|
| 28976-28988 |
Reviews
|
| The emergence of trophoblast cellsurface antigen 2 TROP2 as a novel cancer target |
|
https://doi.org/10.18632/oncotarget.25615
|
| 28989-29006 |
|
| Harnessing RIGI and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment |
|
https://doi.org/10.18632/oncotarget.25626
|
| 29007-29017 |
Corrections
|
| Correction: Intake of red and processed meat and risk of renal cell carcinoma: a metaanalysis of observational studies |
|
https://doi.org/10.18632/oncotarget.25715
|
| 29018-29018 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
